中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
12期
37-39
,共3页
肝炎,酒精性%英夫利昔单抗%药物评价
肝炎,酒精性%英伕利昔單抗%藥物評價
간염,주정성%영부리석단항%약물평개
Hepatitis,alcoholic%Infliximab%Drug evaluation
目的 评价英夫利昔单抗治疗重症酒精性肝炎(SAH)的临床疗效和安全性.方法 计算机检索PubMed、EMbase、Web of Science、OVID和Cochrane图书馆系统评价资料库、CBMdisc和中国期刊网全文数据库(CNKI)等电子数据库,检索时限为建库至2013年3月,以SAH、重症酒精性肝病、英夫利昔单抗、肿瘤坏死因子拮抗剂等名称作为关键词、主题词、自由词,查找英夫利昔单抗治疗SAH的随机对照试验(RCT),对符合纳入标准的临床研究进行Meta分析.结果 共纳入2篇RCT,56例SAH患者,采用英夫利昔单抗(10 mg/kg)联合糖皮质激素(40 mg/d)治疗SAH,可能因严重感染的高患病率而加速患者死亡,预后不良;采用英夫利昔单抗(5 mg/kg)联合糖皮质激素(40mg/d)治疗,具有良好的耐受性,患者的Maddrey评分显著改善.结论 现有的临床证据显示,英夫利昔单抗治疗SAH的疗效和安全性依据不足,需要更多大样本、不同剂量的RCT指导临床.
目的 評價英伕利昔單抗治療重癥酒精性肝炎(SAH)的臨床療效和安全性.方法 計算機檢索PubMed、EMbase、Web of Science、OVID和Cochrane圖書館繫統評價資料庫、CBMdisc和中國期刊網全文數據庫(CNKI)等電子數據庫,檢索時限為建庫至2013年3月,以SAH、重癥酒精性肝病、英伕利昔單抗、腫瘤壞死因子拮抗劑等名稱作為關鍵詞、主題詞、自由詞,查找英伕利昔單抗治療SAH的隨機對照試驗(RCT),對符閤納入標準的臨床研究進行Meta分析.結果 共納入2篇RCT,56例SAH患者,採用英伕利昔單抗(10 mg/kg)聯閤糖皮質激素(40 mg/d)治療SAH,可能因嚴重感染的高患病率而加速患者死亡,預後不良;採用英伕利昔單抗(5 mg/kg)聯閤糖皮質激素(40mg/d)治療,具有良好的耐受性,患者的Maddrey評分顯著改善.結論 現有的臨床證據顯示,英伕利昔單抗治療SAH的療效和安全性依據不足,需要更多大樣本、不同劑量的RCT指導臨床.
목적 평개영부리석단항치료중증주정성간염(SAH)적림상료효화안전성.방법 계산궤검색PubMed、EMbase、Web of Science、OVID화Cochrane도서관계통평개자료고、CBMdisc화중국기간망전문수거고(CNKI)등전자수거고,검색시한위건고지2013년3월,이SAH、중증주정성간병、영부리석단항、종류배사인자길항제등명칭작위관건사、주제사、자유사,사조영부리석단항치료SAH적수궤대조시험(RCT),대부합납입표준적림상연구진행Meta분석.결과 공납입2편RCT,56례SAH환자,채용영부리석단항(10 mg/kg)연합당피질격소(40 mg/d)치료SAH,가능인엄중감염적고환병솔이가속환자사망,예후불량;채용영부리석단항(5 mg/kg)연합당피질격소(40mg/d)치료,구유량호적내수성,환자적Maddrey평분현저개선.결론 현유적림상증거현시,영부리석단항치료SAH적료효화안전성의거불족,수요경다대양본、불동제량적RCT지도림상.
Objective To systematic review the clinical efficacy and safety of infliximab in treatment of severe alcoholic hepatitis (SAH).Methods The electronic database of PubMed,EMbase,Web of Science,OVID and Cochrane systematic review database,CBM disc and CNKI from building the database until March 2013 were retrieved.With "SAH","severe alcoholic hepatitis","infliximab" and "tumor necrosis factor" as key words or free words.Randomized-controlled trials (RCT) on infliximab in treatment of SAH was selected and analyzed by Meta analysis.Results Two RCTs was enrolled,included 56 SAH patients.Infliximab (10 mg/kg) combined with glucocorticoids (40 mg/d) might accelerate death because of the high prevalence of serious infections.Infliximab (5 mg/kg) combined glucocorticoids (40 mg/d) had more tolerability and improved patient's Maddrey scores significantly.Conclusions Existing clinical evidence suggest that it is short of evidence for the clinical efficacy and safety of infliximab.It need guide by large sample of clinically and different doses RCT.
